HEADER HYDROLASE/HYDROLASE INHIBITOR 21-SEP-92 1HEF TITLE THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE- TITLE 2 BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TITLE 3 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT TITLE 4 ORIENTATIONS COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: E; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: SKF 108738 PEPTIDE INHIBITOR; COMPND 7 CHAIN: I; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 MOL_ID: 2; SOURCE 7 SYNTHETIC: YES KEYWDS HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR K.MURTHY,E.L.WINBORNE,M.D.MINNICH,J.S.CULP,C.DEBOUCK REVDAT 7 15-NOV-23 1HEF 1 SEQADV LINK ATOM REVDAT 6 29-NOV-17 1HEF 1 HELIX REVDAT 5 13-JUL-11 1HEF 1 VERSN REVDAT 4 08-SEP-09 1HEF 1 SOURCE REMARK SITE SEQRES REVDAT 4 2 1 HET HETNAM REVDAT 3 24-FEB-09 1HEF 1 VERSN REVDAT 2 01-APR-03 1HEF 1 JRNL REVDAT 1 31-MAY-94 1HEF 0 JRNL AUTH K.H.MURTHY,E.L.WINBORNE,M.D.MINNICH,J.S.CULP,C.DEBOUCK JRNL TITL THE CRYSTAL STRUCTURES AT 2.2-A RESOLUTION OF JRNL TITL 2 HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN JRNL TITL 3 IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE JRNL TITL 4 INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS. JRNL REF J.BIOL.CHEM. V. 267 22770 1992 JRNL REFN ISSN 0021-9258 JRNL PMID 1429626 REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PROLSQ REMARK 3 AUTHORS : KONNERT,HENDRICKSON REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 5.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 3649 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING + TEST SET) : 0.159 REMARK 3 R VALUE (WORKING SET) : NULL REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 806 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 23 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : 0.020 ; 0.025 REMARK 3 ANGLE DISTANCE (A) : 0.044 ; 0.050 REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : 0.055 ; 0.060 REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : 0.219 ; 0.200 REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : 1.700 ; 2.000 REMARK 3 STAGGERED (DEGREES) : 23.700; 15.000 REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE INHIBITOR ALA-ALA-PJJ-VAL-VME IS REMARK 3 DISORDERED AROUND THE TWO-FOLD CYRSTALLOGRAPHIC AXIS. REMARK 3 APPLICATION OF CRYSTALLOGRAPHIC SYMMETRY RESULTS IN THE OVERLAP REMARK 3 OF THE TWO ORIENTATIONS. THE OCCUPANCY OF EACH ORIENTATION IS 1/ REMARK 3 2. REMARK 4 REMARK 4 1HEF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000173809. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : NULL REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : NULL REMARK 200 RESOLUTION RANGE HIGH (A) : NULL REMARK 200 RESOLUTION RANGE LOW (A) : NULL REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.08 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.09 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 7555 Y,X,-Z+1/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+2/3 REMARK 290 10555 -Y,-X,-Z+5/6 REMARK 290 11555 -X+Y,Y,-Z+1/2 REMARK 290 12555 X,X-Y,-Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 27.84000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 55.68000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 41.76000 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 69.60000 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 13.92000 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 27.84000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 55.68000 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 69.60000 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 41.76000 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 13.92000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 HIV-1 PROTEASE IS A SYMMETRIC DIMER, WHILE THE INHIBITOR IS AN REMARK 300 ASYMMETRIC MOLECULE. FURTHERMORE, THE INHIBITOR IS SMALL ENOUGH REMARK 300 TO BE ENTIRELY CONTAINED WITHIN THE ACTIVE SITE OF THE ENZYME REMARK 300 AND, THEREFORE, DOES NOT CONTRIBUTE TO INTER-DIMER CONTACTS. REMARK 300 THUS, OF THE TWO POSSIBLE ORIENTATIONS OF THE INHIBITOR, NEITHER REMARK 300 IS THERMODYNAMICALLY PREFERRED. IN THE CRYSTAL STRUCTURE, REMARK 300 THEREFORE, BOTH ARE REPRESENTED EQUALLY. THE ASYMMETRIC UNIT OF REMARK 300 THE CRYSTAL THUS CONSISTS OF ONE PROTEASE MONOMER, AND ONE COPY REMARK 300 OF EACH OF TWO POSSIBLE ORIENTATIONS OF THE INHIBITOR. EACH COPY REMARK 300 OF THE INHIBITOR REPRESENTS HALF THE TOTAL OCCUPANCY FOR THE REMARK 300 INHIBITOR. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: E, I REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 350 BIOMT2 2 -0.866025 0.500000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 55.68000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH E 100 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 REMARK 400 THE METHYL N-{(2S,4S,5S)-5-[(L-ALANYL-L-ALANYL)AMINO]-2-BENZYL-4- REMARK 400 HYDROXY-6-PHENYLHEXANOYL}-L-VALYL-L-VALINATE IS PEPTIDE-LIKE, A REMARK 400 MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: METHYL N-{(2S,4S,5S)-5-[(L-ALANYL-L-ALANYL)AMINO]-2-BENZYL- REMARK 400 4-HYDROXY-6-PHENYLHEXANOYL}-L-VALYL-L-VALINATE REMARK 400 CHAIN: I REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD2 ASP E 29 N ALA I 201 2.03 REMARK 500 OE1 GLN E 7 O HOH E 116 2.14 REMARK 500 NE1 TRP E 6 O HOH E 113 2.15 REMARK 500 NH1 ARG E 41 O HOH E 118 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 CE MET E 46 CE1 PHE E 53 10555 1.59 REMARK 500 OD2 ASP E 29 CG1 VME I 211 9555 1.94 REMARK 500 OE1 GLN E 2 N GLY E 40 3564 1.95 REMARK 500 CE MET E 46 CD1 PHE E 53 10555 2.10 REMARK 500 OD2 ASP E 29 CM VME I 211 9555 2.10 REMARK 500 ND2 ASN E 98 ND2 ASN E 98 9555 2.13 REMARK 500 CD1 LEU E 10 O HOH E 105 11555 2.14 REMARK 500 OG SER E 37 O HOH E 113 2665 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 VAL E 11 CB - CA - C ANGL. DEV. = 14.4 DEGREES REMARK 500 ASP E 25 CB - CG - OD2 ANGL. DEV. = 8.0 DEGREES REMARK 500 GLU E 34 CB - CG - CD ANGL. DEV. = 20.1 DEGREES REMARK 500 ASN E 36 OD1 - CG - ND2 ANGL. DEV. = -15.1 DEGREES REMARK 500 ILE E 50 CA - C - O ANGL. DEV. = -15.4 DEGREES REMARK 500 ILE E 50 CA - C - N ANGL. DEV. = 25.9 DEGREES REMARK 500 ARG E 57 CD - NE - CZ ANGL. DEV. = 9.8 DEGREES REMARK 500 ARG E 57 NH1 - CZ - NH2 ANGL. DEV. = -8.1 DEGREES REMARK 500 ARG E 57 NE - CZ - NH2 ANGL. DEV. = 8.8 DEGREES REMARK 500 GLN E 58 N - CA - CB ANGL. DEV. = 15.6 DEGREES REMARK 500 GLN E 58 CA - CB - CG ANGL. DEV. = 17.2 DEGREES REMARK 500 ARG E 87 CD - NE - CZ ANGL. DEV. = -9.3 DEGREES REMARK 500 ARG E 87 NE - CZ - NH1 ANGL. DEV. = -6.3 DEGREES REMARK 500 LEU E 97 CA - CB - CG ANGL. DEV. = 14.8 DEGREES REMARK 500 ALA I 202 C - N - CA ANGL. DEV. = 29.7 DEGREES REMARK 500 VME I 211 C - N - CA ANGL. DEV. = 16.8 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ALA I 202 PJJ I 205 111.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN I OF SKF 108738 PEPTIDE REMARK 800 INHIBITOR REMARK 999 REMARK 999 SEQUENCE REMARK 999 THIS VARIANT OF THE HIV 1 PROTEASE HAS ASN AT THE POSITION 36 IN REMARK 999 CHAIN E AS CONFIRMED BY INSPECTION OF THE ELECTRON DENSITY. SEE REMARK 999 REFERENCES 14,15, AND 16 CITED IN J.BIOL.CHEM. V.267:22770, (1992). DBREF 1HEF E 1 99 UNP P03366 POL_HV1B1 69 167 DBREF 1HEF I 201 211 PDB 1HEF 1HEF 201 211 SEQADV 1HEF ASN E 36 UNP P03366 MET 104 CONFLICT SEQRES 1 E 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 E 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 E 99 GLY ALA ASP ASP THR VAL LEU GLU GLU ASN SER LEU PRO SEQRES 4 E 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 E 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 E 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 E 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 E 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 I 5 ALA ALA PJJ VAL VME HET PJJ I 205 22 HET VME I 211 9 HETNAM PJJ (2R,4S,5S)-5-AMINO-2-BENZYL-4-HYDROXY-6-PHENYLHEXANOIC HETNAM 2 PJJ ACID HETNAM VME METHYL L-VALINATE HETSYN VME O-METHYLVALINE FORMUL 2 PJJ C19 H23 N O3 FORMUL 2 VME C6 H13 N O2 FORMUL 3 HOH *23(H2 O) HELIX 1 1 GLY E 86 GLY E 94 1ONLY HELIX IN STRUCTURE 9 SHEET 1 SHE 8 LYS E 43 GLY E 49 0 SHEET 2 SHE 8 GLY E 52 ILE E 66 -1 SHEET 3 SHE 8 HIS E 69 GLY E 78 -1 SHEET 4 SHE 8 THR E 31 GLU E 34 1 SHEET 5 SHE 8 ASN E 83 ILE E 85 -1 SHEET 6 SHE 8 GLN E 18 ASP E 25 1 SHEET 7 SHE 8 PRO E 9 ILE E 15 -1 SHEET 8 SHE 8 GLU E 65 ILE E 66 -1 LINK C ALA I 202 N PJJ I 205 1555 1555 1.31 LINK C PJJ I 205 N VAL I 210 1555 1555 1.34 LINK C VAL I 210 N VME I 211 1555 1555 1.30 SITE 1 AC1 13 ARG E 8 ASP E 25 GLY E 27 ALA E 28 SITE 2 AC1 13 ASP E 29 ILE E 47 GLY E 48 GLY E 49 SITE 3 AC1 13 ILE E 50 PRO E 81 VAL E 82 ILE E 84 SITE 4 AC1 13 HOH E 100 CRYST1 63.070 63.070 83.520 90.00 90.00 120.00 P 61 2 2 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015855 0.009154 0.000000 0.00000 SCALE2 0.000000 0.018308 0.000000 0.00000 SCALE3 0.000000 0.000000 0.011973 0.00000